Retrospective assessment of cyclin‐dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer

Saidy, Behnaz; Rakha, Emad A.; Green, Andrew R.; Ellis, Ian O.; Martin, Stewart G.; Storr, Sarah J.

Abstract

Cyclin‐dependent kinase 5 (Cdk5) is an atypical member of the cyclin‐dependent kinase family and functions as a serine/threonine kinase that can be activated by non‐cyclin binding activators p35 or p39. Cdk5 expression and activity has been linked with the development and progression of cancer; however, its expression in breast cancer has not been fully described. Protein expression of Cdk5 was determined in a large cohort of early‐stage invasive breast cancer tumours (n = 1110) with long‐term follow‐up data using immunohistochemistry. Expression of CDK5 mRNA was assessed in the METABRIC cohort (n = 1980). Low nuclear and cytoplasmic expression of Cdk5 expression was significantly associated with shorter breast cancer‐specific survival (P = .004 and P = .001, respectively). Importantly, low nuclear and cytoplasmic expression of Cdk5 remained associated with survival in multivariate analysis, including potentially confounding factors (hazard ratio (HR) = 0.612, 95% confidence interval (CI) = 0.418‐0.896, P = .011 and HR = 0.507, 95% CI = 0.318‐0.809, P = .004, respectively). In addition, low nuclear and cytoplasmic expression of Cdk5 was significantly associated with clinicopathological criteria associated with adverse patient prognosis. Low CDK5 mRNA expression was associated with shorter patient survival (P = .005) in the METABRIC cohort; no associations between copy gain or loss and survival were observed. These data suggest that low Cdk5 expression is associated with poor clinical outcome of breast cancer patients and may be of clinical relevance.

Citation

Saidy, B., Rakha, E. A., Green, A. R., Ellis, I. O., Martin, S. G., & Storr, S. J. (2020). Retrospective assessment of cyclin‐dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer. Journal of Cellular and Molecular Medicine, 24(11), 6263-6271. https://doi.org/10.1111/jcmm.15268

• Journal Article Type: Article
• Acceptance Date: Mar 26, 2020
• Online Publication Date: Apr 30, 2020
• Publication Date: Jun 1, 2020
• Deposit Date: Oct 12, 2020
• Publicly Available Date: Oct 12, 2020
• Journal: Journal of Cellular and Molecular Medicine
• Print ISSN: 1582-1838
• Electronic ISSN: 1582-4934
• Publisher: Wiley
• Peer Reviewed: Peer Reviewed
• Volume: 24
• Issue: 11
• Pages: 6263-6271
• DOI: https://doi.org/10.1111/jcmm.15268
• Keywords: Molecular Medicine; Cell Biology
• Public URL: https://nottingham-repository.worktribe.com/output/4371547
• Publisher URL: https://onlinelibrary.wiley.com/doi/full/10.1111/jcmm.15268